CollaneX Therapeutics: working on a breakthrough in the fight against fibrosis

Fibrosis is the excessive formation of connective tissue in an organ or tissue; it is known from scars, but it can also occur in the liver as a result of obesity. An unhealthy lifestyle causes liver fibrosis to increase to such an extent that the disease almost begins to take on epidemic proportions, and no medicine is yet available. TNO has built up unique knowledge over the past decade that it wants to co-develop further with market parties into an effective medicine. This is currently being done by the newly founded CollaneX Therapeutics, a spin-off company of TNO. This biotech company will develop medicines against fibrosis, initially during the first phase of development independently, later in collaboration with pharmaceutical companies.